Lin Zhang1, Miaozhen Qiu2, Ying Jin3, Jiao Ji4, Baoxia Li4, Xueping Wang1, Shumei Yan5, Ruihua Xu3, Dajun Yang4. 1. Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou 510060, China. 2. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou 510060, China ; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine Baltimore, MD 21231, USA. 3. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou 510060, China. 4. Department of Experimental Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou 510060, China. 5. Department of Pathology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou 510060, China.
Abstract
BACKGROUND: Targeting the immune checkpoints in solid tumors becomes hot recently. Programmed cell death ligand 1 (PD-L1) is ligand for programmed death 1 (PD-1), which is known to negatively regulate T-cell activation. In the present study, we investigated the expression of PD-L1 in tumor specimens of gastric cancer and its relationships with clinicopathological variables and survival. METHODS: The expression of PD-L1 in 132 surgically resected specimens of stage II and III gastric cancer was evaluated by immunohistochemistry in microarray tissue. RESULTS: Expression of PD-L1 was observed in 50.8% (67/132) of gastric cancer tumor specimens. Patients whose tumor size over 5cm had a higher positive rate of PD-L1 expression. There was no relationship between the expression of PD-L1 and other clinicopathological variables including age, gender, clinical stage, location as well as histological differentiation. PD-L1 positive patients had significantly poorer survival than negative patients. The 5-year survival rates was 83.1% in those with PD-L1 negative patients and 50.7% for PD-L1 positive patients (P<0.001). The multivariate analysis indicated that both PD-L1 positive and Tumor-node-metastasis stage were independent prognostic factors in gastric cancer patients (P=0.001 and 0.025, respectively). CONCLUSIONS: The expression of PD-L1 was found in half of stages II and III gastric cancer patients. Positive of PD-L1 expression indicated poor survival in Chinese stages II and III gastric adenocarcinoma patients. These results may provide the clue for immunotherapy in the adjuvant treatment setting of gastric cancer patients.
BACKGROUND: Targeting the immune checkpoints in solid tumors becomes hot recently. Programmed cell death ligand 1 (PD-L1) is ligand for programmed death 1 (PD-1), which is known to negatively regulate T-cell activation. In the present study, we investigated the expression of PD-L1 in tumor specimens of gastric cancer and its relationships with clinicopathological variables and survival. METHODS: The expression of PD-L1 in 132 surgically resected specimens of stage II and III gastric cancer was evaluated by immunohistochemistry in microarray tissue. RESULTS: Expression of PD-L1 was observed in 50.8% (67/132) of gastric cancer tumor specimens. Patients whose tumor size over 5cm had a higher positive rate of PD-L1 expression. There was no relationship between the expression of PD-L1 and other clinicopathological variables including age, gender, clinical stage, location as well as histological differentiation. PD-L1 positive patients had significantly poorer survival than negative patients. The 5-year survival rates was 83.1% in those with PD-L1 negative patients and 50.7% for PD-L1 positive patients (P<0.001). The multivariate analysis indicated that both PD-L1 positive and Tumor-node-metastasis stage were independent prognostic factors in gastric cancerpatients (P=0.001 and 0.025, respectively). CONCLUSIONS: The expression of PD-L1 was found in half of stages II and III gastric cancerpatients. Positive of PD-L1 expression indicated poor survival in Chinese stages II and III gastric adenocarcinomapatients. These results may provide the clue for immunotherapy in the adjuvant treatment setting of gastric cancerpatients.
Authors: Spencer C Liang; Yvette E Latchman; Janet E Buhlmann; Michal F Tomczak; Bruce H Horwitz; Gordon J Freeman; Arlene H Sharpe Journal: Eur J Immunol Date: 2003-10 Impact factor: 5.532
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Julia A Brown; David M Dorfman; Feng-Rong Ma; Elizabeth L Sullivan; Oliver Munoz; Clive R Wood; Edward A Greenfield; Gordon J Freeman Journal: J Immunol Date: 2003-02-01 Impact factor: 5.422
Authors: Scott E Strome; Haidong Dong; Hideto Tamura; Stephen G Voss; Dallas B Flies; Koji Tamada; Diva Salomao; John Cheville; Fumiya Hirano; Wei Lin; Jan L Kasperbauer; Karla V Ballman; Lieping Chen Journal: Cancer Res Date: 2003-10-01 Impact factor: 12.701
Authors: Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen Journal: Nat Med Date: 2002-06-24 Impact factor: 53.440
Authors: Kazuto Harada; Xiaochuan Dong; Jeannelyn S Estrella; Arlene M Correa; Yan Xu; Wayne L Hofstetter; Kazuki Sudo; Hisashi Onodera; Koyu Suzuki; Akihiro Suzuki; Randy L Johnson; Zhenning Wang; Shumei Song; Jaffer A Ajani Journal: Gastric Cancer Date: 2017-08-11 Impact factor: 7.370
Authors: Aaron T Mayer; Arutselvan Natarajan; Sydney R Gordon; Roy L Maute; Melissa N McCracken; Aaron M Ring; Irving L Weissman; Sanjiv S Gambhir Journal: J Nucl Med Date: 2016-12-15 Impact factor: 10.057
Authors: Elizabeth D Thompson; Marianna Zahurak; Adrian Murphy; Toby Cornish; Nathan Cuka; Eihab Abdelfatah; Stephen Yang; Mark Duncan; Nita Ahuja; Janis M Taube; Robert A Anders; Ronan J Kelly Journal: Gut Date: 2016-01-22 Impact factor: 23.059